TearLab Corporation (www.tearlab.com) develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide.
The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
To see an interview with Ben Sullivan, PhD, Founder and Chief Scientific Officer of TearLab, click on the following link:
http://watch.bnn.ca/the-close/august-2009/the-close-august-7-2009/#clip201357
Specialties
Point of care diagnostics for ocular diseases- Dry eye, Osmolarity Testing, TearLab
New hires at TearLab Corporation
-
Territory Manager
Came from...
PROMETHEUS LABS- Therapeutics and Diagnostics, Technical Territory Specialist-Gastroenterology Specialist
-
TearLab Corporation Company Blog
- Feb 1, 2012
-
Chronic BAK exposure is associated with an increase in tear osmolarity
Jan 28, 2012 - Jan 24, 2012
- Jan 19, 2012
-
Diurnal variation of tear osmolarity in normal subjects measured by a new microchip system
Jan 12, 2012
